Salem AH - Search Results

1

Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.

Samineni D, Huang W, Gibiansky L, Ding H, Zhang R, Li C, Sinha A, Rajwanshi R, Humphrey K, Bazeos A, Salem AH, Miles D. Samineni D, et al. Among authors: salem ah. Adv Ther. 2022 Jan;39(1):598-618. doi: 10.1007/s12325-021-01919-z. Epub 2021 Nov 25. Adv Ther. 2022. PMID: 34822104 Free PMC article. Clinical Trial.

2

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.

Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Agarwal SK, et al. Among authors: salem ah. J Clin Pharmacol. 2016 Nov;56(11):1335-1343. doi: 10.1002/jcph.730. J Clin Pharmacol. 2016. PMID: 26953185 Clinical Trial.

3

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.

Salem AH, Agarwal SK, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL. Salem AH, et al. J Clin Pharmacol. 2016 Nov;56(11):1355-1361. doi: 10.1002/jcph.741. J Clin Pharmacol. 2016. PMID: 27029823 Clinical Trial.

4

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.

Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Jones AK, et al. Among authors: salem ah. AAPS J. 2016 Sep;18(5):1192-1202. doi: 10.1208/s12248-016-9927-9. Epub 2016 May 27. AAPS J. 2016. PMID: 27233802 Clinical Trial.

5

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Konopleva M, et al. Among authors: salem ah. Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12. Cancer Discov. 2016. PMID: 27520294 Free PMC article. Clinical Trial.

6

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.

Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Salem AH, et al. J Clin Pharmacol. 2017 Apr;57(4):484-492. doi: 10.1002/jcph.821. Epub 2016 Nov 15. J Clin Pharmacol. 2017. PMID: 27558232

7

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.

Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, Salem AH. Freise KJ, et al. Among authors: salem ah. Cancer Chemother Pharmacol. 2016 Oct;78(4):847-53. doi: 10.1007/s00280-016-3144-1. Epub 2016 Sep 1. Cancer Chemother Pharmacol. 2016. PMID: 27586967

8

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH. Freise KJ, et al. Among authors: salem ah. Clin Pharmacokinet. 2017 May;56(5):515-523. doi: 10.1007/s40262-016-0453-9. Clin Pharmacokinet. 2017. PMID: 27638334 Clinical Trial.

9

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.

Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL. Agarwal SK, et al. Among authors: salem ah. Br J Clin Pharmacol. 2017 Apr;83(4):846-854. doi: 10.1111/bcp.13175. Epub 2017 Jan 18. Br J Clin Pharmacol. 2017. PMID: 27859472 Free PMC article. Clinical Trial.

10

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.

Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Salem AH, et al. Clin Drug Investig. 2017 Mar;37(3):303-309. doi: 10.1007/s40261-016-0485-9. Clin Drug Investig. 2017. PMID: 27910036 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

298 results

Search Page